Byfavo

RSS

remimazolam

Authorised
This medicine is authorised for use in the European Union.

Overview

Byfavo is a sedative medicine given to adults before a medical test or procedure to make them feel relaxed and sleepy (sedated).

Byfavo contains the active substance remimazolam.

This EPAR was last updated on 20/04/2021

Authorisation details

Product details
Name
Byfavo
Agency product number
EMEA/H/C/005246
Active substance
remimazolam
International non-proprietary name (INN) or common name
remimazolam
Therapeutic area (MeSH)
Conscious Sedation
Anatomical therapeutic chemical (ATC) code
N05CD
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
PAION Netherlands B.V.
Date of issue of marketing authorisation valid throughout the European Union
26/03/2021
Contact address

Vogt 21
6422RK
Heerlen
Netherlands

Product information

26/03/2021 Byfavo - EMEA/H/C/005246 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Psycholeptics

Therapeutic indication

Remimazolam is indicated in adults for procedural sedation.

Assessment history

How useful was this page?

Add your rating